Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTX-4975-05 vs Qutenza in Knee Osteoarthritis
NCT03576508Phase 1Completed
- Sponsor
- Centrexion Therapeutics
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of capsaicin in osteoarthritis (OA) (2 arms), sponsored by Centrexion Therapeutics. Primary endpoints: Capsaicin Pharmacokinetics - AUC0-t at Day 8, Capsaicin Pharmacokinetics - AUC0-inf at Day 8 and 1 more. Started Jun 2018; status: completed.
02
Drugs
capsaicin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03576508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576508.